Celecoxib concentration predicts decrease in prostaglandin E2concentrations in nipple aspirate fluid from high risk women

Table 3 Median concentrations of PGE2 and celecoxib in plasma in ng/ml based on celecoxib dose¹

Population: Dose		Before (N)	After (N	After v.	P value
		Treatment	Treatment	Before(N)	ΔPGE2	Celecoxib Level & ΔPGE₂
200 mg twice daily
Overall	PGE2	0.24(20)	0.22(20)	-0.003(20)	0.70	0.25
	Celecoxib		253.4(20)
Premenopausal	PGE2	0.42(6)	0.33(6)	0.008(6)	1.0
	Celecoxib		195.3(6)
Postmenopausal	PGE2	0.21(14)	0.20(14)	-0.004(14)	0.58
	Celecoxib		267.5(14)
400 mg twice daily
Overall	PGE2	0.29(26)	0.21(26)	-0.016(20)	0.72	0.93
	Celecoxib		759.8(26)
Premenopausal	PGE2	0.37(11)	0.37(11)	-0.0005(11)	0.77
	Celecoxib		227.3(11)
Postmenopausal	PGE2	0.28(15)	0.19(15)	-0.037	0.64
	Celecoxib		860.6(15)

1: N: sample size; NAF: nipple aspirate fluid. P values assess ΔPGE₂ (was the change from before to after treatment significant) and celecoxib level & ΔPGE₂ (was the celecoxib level after treatment related to the change in PGE₂)

ISSN: 1471-2407